Lenalidomide has become one of the most widely used drugs in multiple myeloma, appearing in nearly every phase of treatment from initial diagnosis through long-term maintenance and relapse. It belongs to a class called immunomodulatory drugs, and its influence on myeloma care over the past two decades is difficult to overstate. The story of how it works, when it helps, what risks it carries, and where it fits as treatment evolves is more layered than a single prescription might suggest.
How Lenalidomide Kills Myeloma Cells
Lenalidomide does not work the way most cancer drugs do. Rather than poisoning cells directly or blocking a single growth signal, it hijacks a piece of the cell’s own waste-disposal system. Every cell has molecular machinery that tags unwanted proteins for destruction. Lenalidomide latches onto a protein called cereblon, which is part of one of these tagging machines, and changes what that machine targets. Specifically, it redirects the machine to grab two proteins called Ikaros and Aiolos, which myeloma cells rely on to survive. Once tagged, those proteins get chewed up, and the myeloma cell dies.
This mechanism was worked out in detail over several years. Researchers showed that lenalidomide causes Ikaros and Aiolos to bind to the cereblon-containing complex, leading to their rapid destruction inside the cell.
The same machinery operates in immune cells, but with a different outcome. In T cells, the destruction of Ikaros and Aiolos removes a brake on immune activation rather than killing the cell. The result is a kind of two-pronged attack: the drug directly kills myeloma cells while simultaneously boosting the immune system’s ability to fight them. Lenalidomide activates both T cells and natural killer cells, enhancing the body’s own anti-myeloma response.1PubMed Central. Lenalidomide enhances anti-myeloma cellular immunity This dual action is why the drug is classified as an immunomodulatory agent rather than a straightforward chemotherapy.2PubMed Central. The novel mechanism of lenalidomide activity
Upfront Treatment for Newly Diagnosed Patients
For people who are newly diagnosed with myeloma, lenalidomide almost always shows up in the initial drug combination. The backbone that dominated for years is the three-drug regimen of bortezomib, lenalidomide, and dexamethasone. A major randomized trial compared this triplet against lenalidomide and dexamethasone alone in patients who were not heading straight to a stem-cell transplant. The three-drug combination produced a median time before the disease progressed of about 43 months, compared with 30 months for the two-drug approach. Overall survival was also longer, at roughly 75 months versus 64 months.3PubMed Central. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial That trial essentially cemented the triplet as the standard of care.
More recently, treatment has moved toward four-drug combinations that add a monoclonal antibody to the lenalidomide-based triplet. Two large trials tested this idea. The IMROZ trial added isatuximab, showing an estimated five-year progression-free survival rate of about 63% and deep-response rates (measured by the absence of detectable residual disease) of roughly 56%. The CEPHEUS trial added daratumumab and reported a five-year progression-free survival rate of about 68%, with deep-response rates around 61%.4PubMed Central. Maintenance Therapy in the Era of Quadruplets for Multiple Myeloma: When, What, and for How Long? A systematic review and meta-analysis confirmed that these four-drug regimens produce meaningfully higher rates of deep responses compared with three-drug combinations.5Blood Advances. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis In both designs, lenalidomide continued indefinitely as part of the maintenance backbone after bortezomib was stopped, underscoring its central role in sustained disease control.
Maintenance After Stem-Cell Transplant
For patients who are fit enough to undergo an autologous stem-cell transplant, one of the most impactful uses of lenalidomide comes afterward: long-term maintenance therapy. The idea is simple in principle. Even after a transplant achieves a deep response, tiny numbers of myeloma cells almost always survive, and without ongoing treatment they eventually regrow. Lenalidomide maintenance aims to suppress that regrowth for as long as possible.
The evidence supporting this strategy is strong. An early randomized trial comparing lenalidomide maintenance with placebo after transplant found that median progression-free survival nearly doubled, from about 23 months with placebo to 41 months with lenalidomide.6PubMed. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma A later meta-analysis pooling data from multiple trials reinforced the point: the lenalidomide group had a median progression-free survival of nearly 53 months versus about 24 months without maintenance, and overall survival was also significantly better.7Journal of Clinical Oncology. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis These results are striking enough that post-transplant lenalidomide maintenance has become essentially universal for transplant-eligible patients.
Maintenance is typically given at a lower dose than what is used during initial treatment, and it continues until the disease progresses or side effects become intolerable. For patients who were not candidates for transplant, continuous lenalidomide and dexamethasone has shown that the quality-of-life improvements gained during therapy hold steady over time, meaning the longer duration of treatment does not come at the expense of how patients feel day to day.8PubMed. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone
Lenalidomide in Relapsed or Refractory Myeloma
Lenalidomide first proved itself in patients whose myeloma had already come back or stopped responding to earlier treatment. Two landmark trials, published simultaneously, tested lenalidomide plus dexamethasone against dexamethasone alone in relapsed or refractory patients. Both reached the same conclusion. In one trial, about 60% of patients on lenalidomide responded, compared with roughly 20% on placebo, and the time before the disease worsened more than doubled, from under five months to over eleven months. Survival was also significantly longer.9PubMed. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America The companion trial showed nearly identical results, with response rates of about 60% versus 24% and similar survival gains.10PubMed. Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
These trials were what initially brought lenalidomide into widespread use, and it remains a common ingredient in relapsed-disease regimens today, often combined with newer agents like carfilzomib, ixazomib, or daratumumab rather than dexamethasone alone.
Managing Side Effects
Lenalidomide’s side-effect profile is distinctly different from traditional chemotherapy. Nausea and hair loss, the hallmarks of older cancer drugs, are uncommon. Instead, the main concerns fall into a few specific categories.
Low blood counts are the most frequent problem. Drops in neutrophils (a type of white blood cell important for fighting infection) and platelets (which help blood clot) are common enough that regular blood monitoring is standard practice throughout treatment. When counts fall too low, the dose is reduced or treatment is paused until they recover. A Canadian consensus panel concluded that dose adjustment based on the severity of low counts is the cornerstone of safe lenalidomide use.11PubMed Central. Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus Fatigue is also frequently reported across the various cancers treated with lenalidomide.12PubMed Central. Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
Blood clots represent a more dangerous, though less common, side effect. When lenalidomide is combined with dexamethasone or other agents, the risk of deep vein thrombosis and pulmonary embolism rises. In one study, about 8% of patients developed deep vein thrombosis, and some of those patients were not on any blood clot prevention at the time.13PubMed Central. Thromboembolic events with lenalidomide-based therapy for multiple myeloma As a result, most patients on lenalidomide-based combinations now receive some form of clot-prevention therapy, whether aspirin or a prescription blood thinner, depending on their individual risk factors.
The Question of Second Cancers
One of the more sobering findings from long-term follow-up is that lenalidomide maintenance appears to carry a small but real increase in the risk of developing a second, unrelated cancer. Three large prospective trials observed a significantly higher rate of second cancers in patients who received lenalidomide maintenance after transplant compared with those who did not.14PubMed Central. Secondary Primary Malignancies in Multiple Myeloma: A Review
An individual-patient-data meta-analysis put numbers to this: the five-year cumulative incidence of any second cancer was about 7% with lenalidomide versus roughly 5% without it. The increase was driven primarily by blood cancers, and was especially pronounced when lenalidomide was combined with the older alkylating agent melphalan, a combination that has largely fallen out of favor.15The Lancet Oncology. Risk of second primary malignancies with lenalidomide in patients with multiple myeloma: an individual patient data meta-analysis The consensus view is that the survival benefit of lenalidomide maintenance substantially outweighs this risk, but it is something patients and their doctors weigh explicitly, and it is one reason ongoing monitoring continues throughout maintenance therapy.
Kidney Function and Dose Adjustments
Myeloma itself frequently damages the kidneys, so many patients have impaired kidney function at the time treatment starts. This matters because lenalidomide is cleared almost entirely by the kidneys. About 82% of an oral dose is excreted unchanged in urine within 24 hours.16PubMed Central. Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide When kidney function drops, the drug accumulates in the blood and its effects, both therapeutic and toxic, intensify.
Pharmacokinetic studies have quantified this clearly. As kidney function worsens from mild to moderate to severe impairment, the amount of drug the body is exposed to rises dramatically, roughly doubling to quadrupling depending on severity, and the drug takes much longer to clear the system.17The Journal of Clinical Pharmacology. Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis Formal dose reductions are recommended for anyone with a creatinine clearance below 50 mL/min, and hemodialysis patients require especially careful management since the drug is partially removed by dialysis.18Annals of Pharmacotherapy. Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing
Pregnancy Prevention and the REMS Program
Lenalidomide is an analog of thalidomide, the drug infamous for causing severe birth defects in the 1950s and 1960s. Lenalidomide carries the same teratogenic risk, meaning it can cause devastating harm to a developing fetus. Because of this, access to the drug in the United States is controlled through a strict risk management program called REMS (Risk Evaluation and Mitigation Strategy), mandated by the FDA.
The program requires pregnancy testing for women of childbearing potential: twice before starting treatment, weekly during the first month, and every two to four weeks after that.19PubMed Central. Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000-2020 Both patients and prescribers must be enrolled in the program, and pharmacies can only dispense the drug after confirming that the required steps have been completed. Evaluations of the program have found that it works: patient understanding of the safe-use messages is high, and compliance with birth control precautions has been strong.20PubMed Central. Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
The program adds logistical complexity to an already demanding treatment, and some patients find the monthly surveys and pharmacy coordination burdensome. But given the severity of the potential harm, the safeguards remain firmly in place.
Drug Resistance and Why Lenalidomide Stops Working
Like most cancer therapies, lenalidomide does not keep working forever. Understanding why resistance develops comes back to cereblon, the protein the drug binds to. If the myeloma cell alters cereblon through genetic mutations, deletions of the gene region, or abnormal processing of the genetic instructions for making the protein, lenalidomide loses its grip on the cellular machinery and can no longer trigger the destruction of Ikaros and Aiolos.
Researchers studying patients who had progressed through multiple rounds of immunomodulatory drug therapy found that cereblon abnormalities became steadily more common with each successive line of treatment, until nearly a third of patients who were refractory to pomalidomide (a more potent relative of lenalidomide) harbored some form of cereblon alteration.21PubMed Central. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma This finding has practical implications: once the cereblon pathway is compromised, switching to a drug that works through the same pathway is unlikely to help. Treatment after resistance usually needs to pivot to a completely different mechanism of action.
Cost, Access, and the Generic Landscape
For years, the financial burden of lenalidomide was a defining challenge of myeloma care. The drug was approved by the FDA in 2005, but a generic version did not become available until 2022. During that seventeen-year stretch, the price increased more than twentyfold, and by 2021, lenalidomide alone accounted for over $5.8 billion in Medicare Part D spending.22Annals of Pharmacotherapy. Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing The arrival of generics has begun to bring costs down, though for many patients the expense remains substantial.
Adherence to oral myeloma drugs is a persistent concern. A systematic review covering over 27,000 patients across eight countries found that only about 68% of patients taking oral myeloma therapies, including lenalidomide, were consistently adherent. Roughly 36% discontinued treatment at some point. The factors most associated with poor adherence included older age, multiple other health conditions, taking many medications, and lack of social support.23PubMed Central. Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis Financial hardship may also play a role, though it is harder to isolate in studies. The practical takeaway is that even an effective drug is only as good as patients’ ability and willingness to keep taking it.
Cost comparisons among lenalidomide-based combinations themselves are also relevant. In a United States claims analysis, regimens built around lenalidomide with bortezomib or ixazomib were meaningfully less expensive per month than the combination with carfilzomib, with total healthcare cost differences running into thousands of dollars monthly.24Journal of Managed Care and Specialty Pharmacy. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/remitting multiple myeloma in the United States These differences can influence which regimens patients and insurers choose, especially when clinical outcomes between two options are similar.
Lenalidomide Alongside CAR-T and Next-Generation Agents
Even as newer therapies emerge, lenalidomide is not being replaced so much as it is being combined with them. CAR-T cell therapy, in which a patient’s own immune cells are engineered to attack myeloma, has generated enormous excitement. Preclinical work has shown that lenalidomide enhances the function of CAR-T cells directed against myeloma targets, boosting their ability to kill cancer cells and persist in the body.25Clinical Cancer Research. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma This makes biological sense given lenalidomide’s known T-cell-stimulating properties. Clinical trials exploring this combination in patients are ongoing.
Meanwhile, the understanding of how lenalidomide works at the molecular level has guided the development of next-generation drugs called cereblon E3 ligase modulators, or CELMoDs. Agents like iberdomide and mezigdomide are designed to bind cereblon more tightly, degrade a wider set of targets, and overcome certain resistance mechanisms that make lenalidomide stop working. Early clinical data have been promising, particularly in patients whose disease has progressed through lenalidomide and pomalidomide.26Journal of Clinical Oncology. Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making Rather than signaling lenalidomide’s obsolescence, these newer agents are a direct extension of the science that lenalidomide pioneered, refined to work in settings where the original drug no longer can.